financetom
Business
financetom
/
Business
/
BriaCell Therapeutics Adds Mayo Clinic to Late-Stage Study in Metastatic Breast Cancer
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BriaCell Therapeutics Adds Mayo Clinic to Late-Stage Study in Metastatic Breast Cancer
Jul 15, 2025 5:41 AM

08:16 AM EDT, 07/15/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) on Tuesday said it added the Mayo Clinic to its ongoing Phase 3 clinical study in metastatic breast cancer.

The company's late-stage study now has 69 active clinical sites across 15 states. BriaCell's Phase 3 clinical study is evaluating its lead clinical candidate, Bria-IMT, plus immune check point inhibitor versus physician's choice in advanced metastatic breast cancer (Bria-ABC).

Shares of the company closed down 0.7% at $2.77 on Monday on the Toronto Stock Exchange.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Fortive Q4: EPS Tops, Revenue Misses, CEO Confident In 2025 Recovery
Fortive Q4: EPS Tops, Revenue Misses, CEO Confident In 2025 Recovery
Feb 7, 2025
Fortive Corporation ( FTV ) shares are trading lower after the company reported fourth-quarter results. Revenue grew 2% year-over-year (Y/Y) to $1.620 billion, missing the consensus of $1.624 billion. Core Growth Sales by segments: Intelligent Operating Solutions $710.8 million (+4.1% Y/Y), Precision Technologies $567.7 million (-0.4% Y/Y) and Advanced Healthcare Solutions $341.8 million (+3.2% Y/Y). The company’s adjusted operating margin is up 100 basis points Y/Y to 28.7% in the quarter. Adjusted EPS of $1.17, beating the consensus of $1.12....
Accenture Reportedly Ending Global Diversity, Inclusion Goals
Accenture Reportedly Ending Global Diversity, Inclusion Goals
Feb 7, 2025
09:29 AM EST, 02/07/2025 (MT Newswires) -- Accenture ( ACN ) is discontinuing its global diversity and inclusion goals following an assessment of its internal policies and practices, as well as the US landscape, multiple media outlets reported Friday, citing an internal Accenture ( ACN ) memo sent by chief executive officer Julie Sweet. The company will begin to phase...
Ascentage Pharma Says Underwriters Exercise Option to Buy Additional American Depositary Shares
Ascentage Pharma Says Underwriters Exercise Option to Buy Additional American Depositary Shares
Feb 7, 2025
09:20 AM EST, 02/07/2025 (MT Newswires) -- Ascentage Pharma ( AAPG ) said Friday that underwriters of its US initial public offering have partially exercised an over-allotment option to buy an additional 935,144 American depositary shares at the IPO price of $17.25 per ADS. After the partial exercise of the over-allotment option, the total number of ADSs sold in the...
German packaging firm Gerresheimer exploring sale, Bloomberg News reports
German packaging firm Gerresheimer exploring sale, Bloomberg News reports
Feb 7, 2025
Feb 7 (Reuters) - German medical packaging maker Gerresheimer is exploring a potential sale amid interest from private equity funds, Bloomberg News reported on Friday, citing people familiar with the matter. (Reporting by Devika Nair in Bengaluru; Editing by Devika Syamnath) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved